ClinicalTrials.gg

Program

BEBT-209

A development code. Also written as “BEBT-209 capsules”.

Its studies are mostly in Breast Neoplasms · Triple Negative Breast Neoplasms, led by BeBetter Med.

Furthest: phase 3, since May 29, 20253 company-led studies, 2 open or runningNext primary completion: Jun 2030 (phase 3)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
BeBetter Med32 open or runningphase 3since May 29, 2025Sep 7, 2023Jun 2030phase 3 · NCT07544056

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Sep 7, 2023First study: phase 1 study in Advanced Breast CancerFirst studyNCT06047184 · 100 enrolled · China
  2. May 29, 2025Phase 3 study in Breast NeoplasmsNCT06998108 · 330 planned · China
  3. Apr 13, 2026Phase 3 study in Triple Negative Breast NeoplasmsNCT07544056 · 446 planned · China

Ahead

  1. Jun 2030Primary completion: phase 3 study in Triple Negative Breast NeoplasmsNCT07544056

TargetBeta

Not stated by its company or a source we have read. Most early programs say nothing of it.

Studies

All 3 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07544056Triple Negative Breast Neoplasms · China3RecruitingJun 2030446
NCT06998108Breast Neoplasms · China3RecruitingDec 31, 2025330
NCT06047184Advanced Breast Cancer · China1CompletedJan 30, 2024100

How it is read

Names in the registry

  • “BEBT-209 capsules”, 3 entries

Codes read as this program: BEBT209.

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.